[Changes in the serum pepsinogen level during therapy with acemtacin retard as a measure of gastroduodenal tolerance].
Early indications of the development of gastroduodenal lesions can be obtained with the radioimmunological determination of pepsinogen I in serum. The influence of the non-steroidal anti-inflammatory drug Acemetacin in depot form on the course of the pepsinogen levels in serum was examined during 14 day therapy. Mean and median of pepsinogen I in the whole group of 26 patients did not increase significantly. Likewise no increases of the single pepsinogen levels in serum were seen in 85%. Only 4 patients showed increases of about 20 to 27% compared with the initial values. These results indicate that Acemetacin with prolonged action is well tolerated and has only mean influence on the integrity of the mucosa.
Kullich
W
W
Ludwig-Boltzmann-Institut für Rehabilitation interner Erkrankungen, Saalfelden.
Klein
G
G
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004386:Duodenum; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010435:Pepsinogens / Q000097:blood*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D010435:Pepsinogens; C026784:acemetacin; D007213:Indomethacin
Veränderungen der Serumpepsinogen-spiegel unter der Therapie mit Acemetacin retard als Mass der gastroduodenalen Verträglichkeit.